Dr. António Rodrigues is a former Member of the Executive Board and CFO of Banco Comercial Português (BCP) between 1995 and 2008. Dr. Rodrigues began his career at KPMG – Peat Marwick as an auditor and consultant in Madrid and London. Manager and later Senior Manager of the Lisbon office, he was responsible for Banking and Insurance. In 1989, he joined Banco Comercial Português as General Manager and became Head Planning and Research responsible for listing in NYSE and SEC reporting. In 1995, he was appointed Executive Managing Director of Banco Comercial Português and in 2000 became Deputy Chairman of Servibanca, the BCP Group Service Company. He also served as Member of the Board of ActivoBank, Seguros e Pensões Gere, and of Banco Comercial Português Foundation. In 2007 became Deputy Chairman of MillenniumBCP Fortis Grupo Segurador. Group CFO from 1995 to 2008, in different occasions was also responsible for Privat Banking, audit, security, AML, Risk Office, Corporate Center, Accounting, Management information systems, Investors Relations and Legal Office. During 2002 and 2003 was Member of the Board of Directors and Chairman of the Audit Committee of Eureko B.V., Amsterdam.
In 2007 was appointed member of the Supervisory Board of the Euronext, NV, the European holding of NYSE Euronext, position held until the end of 2009. Dr. Rodrigues holds a degree in Business and Administration from the University of Lisbon.
Dr. Rodrigues is a member of the Advisory Board of D. Luís Foundation, Cascais, Portugal. Dr. Rodrigues is currently a Partner at Multi-Family Office.
Professor Eric Jan received in PhD in Developmental Biology: Gene Regulation from Northwestern University in Chicago (USA) in 1999. Thereafter, he pursued postdoctoral work (1999-2006) at Stanford University with Professor Peter Sarnow – a renowned virologist and member of the prestigious United States National Academy of Sciences (USA). In 2006, Eric Jan joined the University of British Columbia (Vancouver, Canada) as an Assistant Professor; he was promoted to Associate Professor in 2011 and to Full Professor in 2018. Professor Eric Jan’s laboratory is particularly interested in studying the mechanisms by which RNA viruses infect host cells and achieve maximal viral replication.
Over the years the work of Professor Jan has shed important light into the precise molecular underpinnings by which viral RNA elements (IRES) mechanisms hijack the ribosome to favour the translation of viral proteins while simultaneous disrupting the translation of host proteins. Professor Eric Jan has published upwards of 50 refereed publications in notable journals including Science, Cell and Nature Biotechnology.
He has also served in numerous academic committees as an adjudicator and as a reviewer in various grant panels.
Professor Hans Peter Wessel received his PhD (Dr. rer. nat.) from the University of Hamburg, Germany in 1981 with a thesis on natural products/carbohydrate chemistry. Thereafter, he worked as a Research Associate in the Division of Biological Sciences of the National Research Council of Canada in Ottawa, Canada, synthesizing artificial carbohydrate antigens to study carbohydrate/ protein interactions with monoclonal antibodies. In 1983, he joined the pharmaceutical company F.Hoffmann-La Roche Ltd in Basel, Switzerland, as a lab head and then project leader.
Increasingly, he assumed managerial positions as a member of the Chemistry Management Team in Basel and the Global Chemistry Management Team. In 2001, he was promoted into the Roche directorate.
Since 2011, Professor Hans Peter Wessel is an Invited Full Professor at the University of Aveiro, Portugal. He is an author in over one hundred publications and patents. From 1996 to 2012 he served as Associate Editor for the Journal of Carbohydrate Chemistry.
He is a former and present member of several Scientific Advisory Boards.
Professor João Nuno Moreira received his PhD in Pharmaceutical Technology in 2002 from the University of Coimbra (Coimbra, Portugal). He performed part of his PhD training in Professor Terry Allen’s group at the University of Alberta (Edmonton, Canada). In 2002, following his PhD graduation, he joined the Faculty of Pharmacy at University of Coimbra as an Assistant Professor becoming a Tenured Assistant Professor in 2007 and a Full Professor in 2014 at that same Institution.
His scientific activity has been focused on the design of lipid based nanosystems for drug and nucleic acid delivery. He has published over 65 manuscripts in peer-reviewed journals, co-edited one book, co-authored 12 book chapters and filed 10 patents. Three of these patents have been granted in the USA, while 2 have been granted in Europe. Professor João Nuno Moreira lectured numerous advanced courses nationally and internationally including a course on Principles and Practice in Drug Development at MIT, Boston, USA in 2007, 2009, 2011-2014, 2016 and 2017.
In 2010, Professor João Nuno Moreira received an Education Innovation Award within the scope of the MIT-Portugal Portugal.
Also in 2010, he co-founded TREAT U – a spin-off company from the University of Coimbra, Portugal.
Professor Karl Kunzelmann received his M.D. from the University of Freiburg in 1985, with a thesis entitled “Beneficial effects of the percutaneous transhepatic drainage for the therapy of obstructive jaundice“. Following a brief clinical practice at the County Hospital in Karlsruhe, he pursued post-doctoral studies with Professor Rainer Greger at the University of Freiburg. In 1990, Professor Kunzelmann became a Research Fellow and later a Lecturer at several distinguished institutions, including the University of California, San Francisco (UCSF, USA), the University of Freiburg (Germany), the Mayo-Clinic Scottsdale (USA), and the Universities of Sydney and Queensland (Australia). In 2003, he took up the position of Professor in Physiology C2 at the Department of Physiology of the University of Regensburg (Germany). In 2013, he was nominated Permanent Visiting Professor at the University of Lisbon (Portugal).
Professor Kunzelmann has co-authored close to three hundred peer-reviewed original papers and reviews in high-rank scientific journals including Cell, Nature Communications and PNAS, for some of which he has also served as referee. He currently serves as a member of the Editorial Board of the European Journal of Physiology.
He is interested in the study of epithelial ion transport in airways, intestine, and kidney in physiological and pathological states including: asthma, cystic fibrosis, polycystic kidney disease (ADPKD) as well as intestinal cancer and inflammatory cell death. Professor Kunzelmann’s work has received extensive recognition. Most recently, Professor Kunzelmann received the 2018 Gilead Research Award.
Dr. Kevin Hudson received his PhD in Molecular and Cell Biology, University of Leicester, United Kingdom in 1988. That same year, Dr. Kevin Hudson joined ICI Pharmaceuticals – later renamed Zeneca and subsequently, following the merger with the Swedish company Astra, AstraZeneca (Alderley Park, United Kingdom). Dr. Kevin Hudson initiated his career as a Senior Scientist in 1988, progressing to management positions including Team Leader in 1993 and Section Leader in Oncology R&D (Bioscience) in 2001 – a position that he held up until 2016. Most recently (2016-present), Dr. Kevin Hudson has worked in Medical Communications (2theNth – Adelphi Group), supporting the launch of new medicines in the Immunology area. He carries extensive drug discovery and development experience from a longstanding career in Pharmaceuticals.
He has specific expertise in Molecular Pharmacology and Oncology and held a range of management positions in these areas, including that of Section Leader. In addition, he has broad experience in leading externally facing interactions, including academic collaborations, partnerships with Biotech and not-for-profit sectors, evaluation of business development opportunities and working with clinical phase CROs.
Professor Michel Roberge received his PhD (Dr. rer. nat.) from the University of Heidelberg in 1985. Thereafter, he did postdoctoral training at the University of California (Davis) between 1985-1989 and at the Institut Suisse de Recherches Expérimentales sur le Cancer (Lausanne, Switzerland) from 1990-1991. He joined the University of British Columbia (Vancouver, Canada) in 1991 as an Assistant Professor in the Department of Biochemistry and Molecular Biology and progressed through the ranks of Associate Professor in 1996 to Full Professor in 2003. Professor Michel Roberge is a chemical biologist who authored ~150 original articles, review articles, book chapters and patents.
He was the recipient of the Arthur E. Schwarting Award granted in 2002 by The American Society of Pharmacognosy and member in numerous scholarly committees. He was a co-founder of the Centre for Drug Research and Development and served as its Scientific Director between 2010 and 2013.
Professor Raymond J. Andersen obtained his M.Sc. in Chemical Physics from the University of California (UC), Berkeley (USA) in 1970 and later, under the supervision of Professor D. John Faulkner from the Scripps Institution of Oceanography (SIO), he received his Ph.D. on Marine Natural Products Chemistry by the UC, San Diego in 1975. He then worked briefly as a Postdoctoral Fellow at the Massachusetts Institute of Technology (MIT), Cambridge, MA (USA) and was later hired as Visiting Assistant Professor at the University of Alberta, Edmonton (Canada). During the Summer of 1977, Professor Andersen moved to the University of British Columbia (Canada) where he developed most of his academic career up to Full Professor in 1987, a position he holds until present day. Professor Andersen’s work has mostly focused on isolation and structure elucidation of novel organic metabolites, produced by marine organisms, with potential for the development of pharmaceutical agents (e.g. antibiotics) in attendance of human pathologies, as well as unravelling its central roles in the biology of the producing organism, thus contributing to better understand their metabolism.
Over the years Professor Andersen has been awarded multiple times for his scientific achievements, including the Rutherford Medal in Chemistry from the Royal Society of Canada (1988), the Arthur E. Schwarting Award from the American Society of Pharmacognosy (2003), the R.U. Lemieux Award from the Canadian Society for Chemistry (2009) and the Paul J. Scheuer Award in Marine Natural Products Chemistry (2012).
Dr. João Marques de Carvalho completed his degree in Medicine from the Faculty of Medical Sciences at NOVA University in Lisbon (Portugal) in October 1980. Dr. Marques de Carvalho did his Medical Internship at the Torres Vedras District Hospital between 1981 and 1982. In 1983, he joined the Medical Services Team at the Torres Vedras District Hospital. That same year, he was appointed to the role of Clinical Manager at the Barro’s Sanatorium in Dr. José Maria Antunes Junior’s Hospital (Torres Vedras) and held this post until 1995. In 1986, he became Clinical Director of Da Graça Clinic Ltd. in Torres Vedras, up until 1995.
Between 1984-1989, he served as a member of the Medical National Board for the South Regional Section. Between 1990 and 2015, he served as Medical Director of the clinical services of BCP Bank. Dr. Marques de Carvalho was nominated Interim Clinical Director of MÉDIS between 2011-2012. Between 2011 and 2015, he was a representative Member of the BCP Bank at the Institute for Hygiene and Tropical Medicine of the NOVA University in Lisbon. Dr. Marques de Carvalho has been responsible for establishing the partnerships between the BCP Bank (and its affiliate insurance branches) with the Medical Clinic of University of Navarra in Pamplona (Spain), since 1991.
As of November 11th of 2016, Dr. Marques de Carvalho joined MyFamily Health (the medical branch of MFO | Multi Family Office) in the capacity of Clinical Director.
We are a team of talented young scientists, medical doctors and financial analysts dedicated to the pursuit of the development of a treatment for COVID-19 and other opportunistic viral infections.
T: +351 916 817 150
© 2020 PrimerGen Ltd. | Design by CIGA
All rights reserved PrimerGen Ltd.